In addition, elevated immune checkpoint expression of PD-1 and PD-L1 was demonstrated in the immune microenvironment of MSI-H colorectal cancer (CRC), and a phase II study of pembrolizumab in CRC patients showed an increased rate in immune-related objective response in MSI-H-CRC compared with MSS-CRC [60]. This evidence concerns the gene CD274 and colorectal cancer.